Global Lutetium-177 Market Dynamics and Trends: Market Scale is Prospected to Hit $295.34 Million by 2029

Global Lutetium-177 Market Overview

According to Global Market Monitor, the global Lutetium-177 market size is $109.23 million in 2024 and is expected to grow to $295.34 million by 2029.

Lu-177 is an ideal isotope for radiopharmaceutical therapy as its half-life makes it easier to combine Lu-177 with numerous biologically active compounds.

Market News

In June 2024 Curium, a world leader in nuclear medicine, announced that it has signed a long-term partnership with the Institut Laue–Langevin (ILL) for irradiation services at their high-flux nuclear reactor in Grenoble, France to produce non-carrier added lutetium-177 (Lu-177). Curium’s Lu-177 program will benefit more than 100,000 critically ill patients worldwide over the next five years.

Regional Market

The Asia-Pacific region is home to 60% of the world's population (approximately 4.3 billion people), including China and India, the world's most populous countries. In the Asia-Pacific region, cancer is the second leading cause of death after cardiovascular disease. The cancer incidence in Asia accounts for 49.3% of the global cancer incidence. With the economic development of the Asia Pacific region, the rapid improvement of the health care system, the high prevalence of cancer in the region, and the increase in investment in the field of nuclear medicine will promote the market demand for Lutetium-177 in the region.

Market Drivers

Cancer is a complex disease caused by uncontrolled growth and division of abnormal cells in the body. It could occur in almost any part of the body and spread to other parts through the bloodstream or lymphatic system. The incidence of cancer is rising across the world. According to the World Health Organization (WHO), cancer is the second leading cause of death globally. Additionally, the National Cancer Institute (NCI) indicated that the number of people living with cancer in the U.S. is expected to reach 22.2 million by 2030, a significant increase from the 16.9 million cancer survivors in 2019. The rise in the prevalence of cancer has driven the development of new and innovative cancer treatments. Lutetium-177 is a therapeutic radiopharmaceutical that has shown promising results in the treatment of various types of cancer. For example, when Lutetium-177 binds to the PSMA ligand, the conjugate is injected into the patient's body. These conjugates will connect to the PSMA receptor on the surface of the cancer cells and kill the cancer cells by emitting β radiation. This treatment has been proven to cure diseases such as prostate cancer and bone cancer. With the increase in the number of cancer patients, the Lutetium-177 industry will be more valued and developed to a high degree.

Drivers	The number of people suffering from cancer worldwide is growing rapidly. Increase investment in the development of new therapeutic and diagnostic drugs Advances in Imaging Technology
Challenges	Storage and transportation difficulties restrict the development. Have higher requirements for patients Industry barriers are high and market supervision is strict.